Mike Kagey

Vice President, Translational Medicine Leap Therapeutics

Seminars

Thursday 25th September 2025
Plasma DKK1 Levels are Associated with DKN-01 Clinical Activity in Colorectal Cancer
11:30 am
  • Peripheral DKK1 is elevated in many cancers, often leading to worse clinical outcomes
  • DKN-01 in combination with standard of care therapy has demonstrated compelling clinical data in CRC with enhanced activity in patients with elevated plasma DKK1
  • CDx development of a plasma DKK1 ELISA assay is undergoing development to support the DKN-01 CRC clinical program
Mike Kagey